Analysts expect Champions Oncology Inc (NASDAQ:CSBR) to announce $7.83 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Champions Oncology’s earnings. The lowest sales estimate is $7.45 million and the highest is $8.20 million. Champions Oncology posted sales of $6.69 million in the same quarter last year, which would indicate a positive year over year growth rate of 17%. The firm is scheduled to issue its next quarterly earnings results on Monday, December 16th.
On average, analysts expect that Champions Oncology will report full-year sales of $32.71 million for the current financial year, with estimates ranging from $32.42 million to $33.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $40.32 million, with estimates ranging from $40.00 million to $40.64 million. Zacks’ sales averages are an average based on a survey of research firms that cover Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.09). The company had revenue of $6.74 million during the quarter, compared to the consensus estimate of $7.50 million. Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%.
CSBR has been the subject of a number of recent analyst reports. Janney Montgomery Scott lowered Champions Oncology from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 24th. ValuEngine raised Champions Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised Champions Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Roth Capital initiated coverage on Champions Oncology in a research report on Friday, September 20th. They issued a “buy” rating and a $9.25 target price for the company. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Champions Oncology currently has an average rating of “Buy” and a consensus target price of $13.13.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CSBR. River & Mercantile Asset Management LLP purchased a new stake in shares of Champions Oncology during the 2nd quarter valued at about $1,082,000. Wells Fargo & Company MN increased its position in shares of Champions Oncology by 110.4% during the 2nd quarter. Wells Fargo & Company MN now owns 149,100 shares of the biotechnology company’s stock valued at $1,167,000 after purchasing an additional 78,250 shares during the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Champions Oncology by 69.1% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 55,000 shares during the last quarter. Wedge Capital Management L L P NC purchased a new stake in shares of Champions Oncology during the 2nd quarter valued at about $277,000. Finally, BlackRock Inc. increased its position in shares of Champions Oncology by 12.0% during the 2nd quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock valued at $1,073,000 after purchasing an additional 14,733 shares during the last quarter. 51.62% of the stock is owned by hedge funds and other institutional investors.
Shares of CSBR stock traded down $0.04 during mid-day trading on Thursday, reaching $5.26. 27,400 shares of the company’s stock traded hands, compared to its average volume of 41,816. Champions Oncology has a 12 month low of $5.01 and a 12 month high of $14.04. The company’s 50-day moving average price is $5.72 and its 200-day moving average price is $7.15. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 2.06. The company has a market cap of $61.00 million, a P/E ratio of 526.00 and a beta of 1.15.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Article: What strategies should day traders use to execute a trade?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.